Tacrolimus: A new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 22, Issue 3, 1998, Pages 217-225

  Jacobson, P ^a   Uberti, J ^b   Davis, W ^a   Ratanatharathorn, V ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Allogeneic bone marrow transplantation; FK506; Graft versus host disease; Peripheral blood stem cell transplantation; Tacrolimus

Indexed keywords

CALCINEURIN; CYCLOSPORIN; INTERLEUKIN 2; METHOTREXATE; PHOSPHORYLASE; TACROLIMUS;

ADVANCED CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; GENE EXPRESSION; GINGIVA HYPERPLASIA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SIBLING; SURVIVAL;

EID: 0031829950     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701331     Document Type: Review

References (129)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 324: 667-674.
2. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
3. Storb R, Leisenring W, Deeg HJ et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine vs methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood 1994: 83: 2749-2750 (letter).
4. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versushost disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
5. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. New Engl J Med 1993; 329: 1225-1230.
6. von Bueltzingsloewen A, Belanger R, Perreault C et al. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. Blood 1993; 81: 849-855.
7. Storb R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119-125.
8. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
9. Storb R, Pepe M, Deeg HJ et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graftversus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 1992; 80: 560-561 (letter).
10. Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249-1255.
11. Klintmalm GB. FK506: an update, Clin Transplant 1994; 8: 207-210.
12. Warty V, Diven W, Cadoff E et al. FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. Transplantation 1988; 46: 453-455.
13. Yoshimura N, Matsui S, Hamashima T et al. A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells, as well as the induction of alloreactivity. Transplant Proc 1989; 21: 1045-1047.
14. Thomas J, Matthews C, Carroll R et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. Transplantation 1990; 49: 390-396.
15. Yoshimura N, Matsui S, Hamashima T et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation 1989; 47: 356-359.
16. Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40: 1256-1265.
17. Goto T, Kino T, Hatanaka H et al. FK506: historical perspectives. Transplant Proc 1991; 23: 2713-2717.
18. Fung JJ, Eliasziw M, Todo S et al. The Pittsburgh' randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183: 117-125.
19. Shapiro R, Jordan ML, Scantlebury VP et al. Tacrolimus in renal transplantation. Transplant Proc 1996; 28: 2117-2118.
20. Jordan ML, Naraghi R, Shapiro R et al. Tacrolimus rescue therapy for renal allograft rejection - five-year experience, Transplantation 1997; 63: 223-228.
21. Shapiro R, Scantlebury VP, Jordan ML et al. Tacrolimus in pediatrie renal transplantation. Transplantation 1996; 62: 1752-1758.
22. Armitage JM, Kormos RL, Morita S et al. Clinical trial of FK506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992; 54: 205-210; discussion 210-211.
23. Pham SM, Kormos RL, Hauler BG et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996; 111: 764-772.
24. Shaw KT, Ho AM, Raghavan A et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995; 92: 11205-11209.
25. Mouzaki A, Rungger D. Properties of transcription factors regulating interleukin-2 gene transcription through the NFAT binding site in untreated or drug-treated naive and memory T-helper cells. Blood 1994; 84: 2612-2621.
26. Bishop DK, Li W. Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. J Immunol 1992; 148: 1049-1054.
27. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-430.
28. Jain AB, Venkataramanan R, Cadoff E et al. Effect of hepatic dysfunction and T tube clamping on FK506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22: 57-59.
29. Jusko WJ, Piekoszewski W, Klintmalm GB et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-290.
30. Prograf Package Insert. Fujisawa: Deerfield, IL, USA, 1994.
31. Venkataramanan R, Jain A, Warty VS et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991; 23: 2736-2740.
32. Fay JW, Wingard JR, Antin JH et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996; 87: 3514-3519.
33. Nash RA, Etzioni R, Storb R et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746-3753.
34. Warty V, Venkataramanan R, Zendehrouh P et al. Distribution of FK506 in plasma lipoproteins in transplant patients. Transplant Proc 1991; 23: 954-955.
35. Nagase K, Iwasaki K, Nozaki K et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 1994; 46: 113-117.
36. Hooks MA. Tacrolimus, a new immunosuppressant - a review of the literature. Ann Pharmacother 1994; 28: 501-511.
37. Venkataramanan R, Jain A, Cadoff E et al. Pharmacokinetics of FK506: preclinical and clinical studies. Transplant Proc 1990; 22: 52-56.
38. Prasad TN, Stiff DD, Subbotina N et al. FK506 (tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res Commun Chem Pathol Pharmacol 1994; 84: 3546.
39. Shiraga T. Matsuda H, Nagase K et al. Metabololism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 1994; 47: 727-735.
40. Christians U, Braun F, Kosian N et al. High performance liquid Chromatography/mass spectrometry of FK506 and its metabolites in blood, bile and urine of liver grafted patients. Transplant Proc 1991; 23: 2741-2744.
41. Lemoine A, Azoulay D, Dennison A et al. FK506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation. Hepatology 1994; 20: 1472-1477.
42. Jain AB, Abu-Elmagd K, Abdallah H et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion (see comments). J Clin Pharmacol 1993; 33: 606-611.
43. Venkataramanan R, Jain A, Warty VW et al. Pharmacokinetics of FK506 following oral administration: a comparison of FK506 and cyclosporine. Transplant Proc 1991; 23: 931-933.
44. Iwasaki K, Shiraga T, Matsuda H et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995; 23: 28-34.
45. Blazar BR, Taylor PA, Fitzsimmons WE et al. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. J Immunol 1994; 153: 1836-1846.
46. Yu C, Storb R, Deeg HJ et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. Bone Marrow Transplant 1996; 17: 649-653.
47. Koehler MT, Howrie D, Mirro J et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 1995; 15: 895-899.
48. Kanarnaru A, Takemoto Y, Kakishita E et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant 1995; 15: 885-889.
49. Bloom E, Abu-Elmagd K, Barnes J et al. Use of FK506 for graft-versus-host disease (GVHD) following bone marrow transplantation (BMT). J Cell Biochem 1994; (Suppl. 18B): 90 (Abstr. G401).
50. Hiraoka AF. Results of a phase III study on prophylactic use of FK506 for acute GVHD compared with cyclosporin in allogeneic bone marrow transplantation. Blood 1997; 90: 561 (Abstr. 2500).
51. Uberti JP, Silver SM, Adams PW et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1997; 19: 1233-1238.
52. Uberti JP, Scalzo A, Hammelef K et al. Allogeneic peripheral blood stem cell transplantation for hematologic malignancy: the efficacy of tacrolimus in the prevention of acute graftversus-host disease. Blood 1997; 90: 393b (Abstr. 4514).
53. Przepiorka D, IppoIiti C, Khouri I et al. Allogeneic transplantalion for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation 1996; 62: 1806-1810.
54. Ratanatharathorn V, Nash RA, Devine SM et al. Phase III study comparing tacrolimus (Prograf, FK506) with cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation (BMT). Blood 1996; 88: 459a (Abstr. 1826).
55. Nash RA, Pineiro LA, Storb R et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634-3641.
56. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-4389.
57. Devine SM, Geller RB, Lin LB et al. The outcome of unrelated donor marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low-dose methotrexate for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 1997; 3: 25-33.
58. Nash RA, Antin J, Karanes C et al. Phase III study comparing tacrolimus (FK506) with cyclosporine (CSP) for prophylaxis of acute graft-versus-host disease (GVHD) after marrow transplantation from unrelated donors. Blood 1997; 90: 561a (Abstr. 2499).
59. Wingard JR, Nash RA, Przepiorka D et al. Relationship of tacrolimus (Prograf. FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Blood 1996; 88: 459a (Abstr. 1829).
60. Platz KP, Mueller AR, Blumhardt G et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58: 170-178.
61. McCauley J. The nephrotoxicity of FK506 as compared with cyclosporine. Curr Opin Nephrol Hypertens 1993; 2: 662-669.
62. Ayres RC, Dousset B, Wixon S et al. Peripheral neurotoxicity with tacrolimus. Lancet 1994; 343; 862-863 (letter).
63. Freise CE, Rowley H, Lake J et al. Similar clinical presentation of neurotoxicity following FK506 and cyclosporine in a liver transplant recipient. Transplant Proc 1991; 23: 3173-3174.
64. Frank B, Perdrizet GA, White HM et al. Neurotoxicity of FK506 in liver transplant recipients. Transplant Proc 1993; 25: 1887-1888.
65. Wijdicks EF, Wiesner RH, Dahlke LJ et al. FK506-induced neurotoxicity in liver transplantation. Ann Neurol 1994; 35: 498-501.
66. Mueller AR, Platz KP, Bechstein WO et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58: 155-170.
67. Small SL, Fukui MB, Bramblett GT et al. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506). Ann Neurol 1996; 40: 575-580.
68. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. New Engl J Med 1996; 334: 494-500.
69. Gruessner RW, Sutherland DE, Drangstveit MB et al. Use of FK506 in pancreas transplantation. Transplant Int 1996; 9 (Suppl 1): S251-S257.
70. Scantlebury V, Shapiro R, Fung J et al. New onset of diabetes in FK506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169-3170.
71. Tanabe K, Koga S, Takahashi K et al. Diabetes mellitus after renal transplantation under FK506 (tacrolimus) as primary immunosuppression. Transplant Proc 1996; 28; 1304-1305.
72. Tabasco-Minguillan J, Mieles L, Carroll P et al. Long-term insulin requirement after liver transplantation with FK506 in American veterans. Transplant Proc 1993; 25: 677-678.
73. Taler SJ, Textor SC, Canzanello VJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588-1592.
74. Williams R, Neuhaus P, Bismuth H et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. Transplant Int 1996; 9 (Suppl. 1): S144-S150.
75. Kusne S, Fung J, Alessiani M et al. Infections during a randomized trial comparing cyclosporine to FK506 immunosuppression in liver transplantation. Transplant Proc 1992; 24: 429-430.
76. Alessiani M, Kusne S, Fung JJ et al. CMV infection in liver transplantation under cyclosporine or FK506 immunosuppression. Transplant Proc 1991; 23: 3035-3037.
77. Hadley S, Samore MH, Lewis WD et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851-859.
78. Singh N, Gayowski T, Wagener M et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. Transplantation 1994; 58: 774-778.
79. Singh N, Gayowski T, Wagener M et al. Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. Transplantation 1996; 61: 396-401.
80. Reyes J, Tzakis A, Green M et al. Post-transplant lymphoproliferative disorders occurring under primary FK506 immunosuppression. Transplant Proc 1991; 23: 3044-3046.
81. Newell KA, Alonso EM, Whitington PF et al. Post-transplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62: 370-375.
82. Deschler DG, Osorio R, Ascher NL et al. Post-transplantation lymphoproliferative disorder in patients under primary tacrolimus (FK506) immunosuppression. Arch Otolaryngol Head Neck Surg 1995; 121: 1037-1041.
83. DiGiuseppe JA, Bas tacky SI, Shirey RS et al. Tacrolimusrelated post-transplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. Arch Pathol Lab Med 1996; 120: 282-285.
84. Mach-Pascual S, Samii K, Beris P. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol 1996; 52: 310-312.
85. Kaplan B, Wang Z, Abecassis MM et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation 1996; 62: 1174-1175.
86. Andoh TF, Burdmann EA, Fransechini N et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996: 50: 1110-1117.
87. Peters DH, Fitton A, Plosker GL et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746-794.
88. Alessiani M, Cillo U, Fung JJ et al. Adverse effects of FK506 overdosage after liver transplantation. Transplant Proc 1993; 25: 628-634.
89. Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 1995; 12: 348-357.
90. Wallemacq PE, Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical and analytical aspects. Clin Chem 1993; 39: 2219-2228.
91. Kumano K, Chen J, He M et al. Role of endothelin in FK506-induced renal hypoperfusion in rats. Transplant Proc 1995; 27: 550-553.
92. Moutabarrik A, Ishibashi M, Fukunaga M et al. FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. Transplant Proc 1991; 23: 3133-3136.
93. Yamada K, Sugisaki Y, Akimoto M et al. FK506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney - morphologic and biologic analysis. Transplant Proc 1992; 24: 1396-1398.
94. Su Q, Weber L, Le Hir M et al. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Ren Physiol Biochem 1995; 18: 128-139.
95. Ichihashi T, Naoe T, Yoshida H et al. Haemolytic uraemic syndrome during FK506 therapy. Lancet 1992; 340: 60-61 (letter).
96. Gharpure VS, Devine SM, Holland HK et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 715-716.
97. McCauley J, Bronsther O, Fung J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet 1989; 2: 1516 (letter).
98. Kaufman DB, Kaplan B, Kanwar YS et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. Transplantation 1995; 59: 1737-1739.
99. Rilo HL, Zeng Y, Alejandro R et al. Effect of FK506 on function of human islets of Langerhans. Transplant Proc 1991; 23: 3164-3165.
100. Carroll PB, Rilo H, Reyes J et al. FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc 1991; 23: 3171-3172.
101. Tamura K, Fujimura T, Tsutsumi T et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta cell. Transplantation 1995; 59: 1606-1613.
102. Masaoka T, Shibata H, Kakishita E et al. Phase II study of FK506 for allogeneic bone marrow transplantation. Transplant Proc 1991; 23: 3228-3231.
103. Devine SM, Newman NJ, Siegel JL et al. Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. Bone Marrow Transplant 1996; 18: 569-572.
104. Boeve BF, Kimmel DW, Aronson AE et al. Dysarthria and apraxia of speech associated with FK-506 (tacrolimus). Mayo Clin Proc 1996; 71: 969-972.
105. Dawson TM, Steiner JP, Lyons WE et al. The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience 1994; 62: 569-580.
106. de Groen PC, Aksamit AJ, Rakela J et al. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. New Engl J Med 1987; 317: 861-866.
107. Schwartz RB, Bravo SM, Klufas RA et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995; 165: 627-631.
108. Thompson CB, June CH, Sullivan KM et al. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 1984; 2: 1116-1120.
109. Backman L, Nicar M, Levy M et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side-effects. Transplantation 1994; 57: 519-525.
110. Fung JJ, Alessiani M, Abu-Elmagd K et al. Adverse effects associated with the use of FK506. Transplant Proc 1991; 23: 3105-3108.
111. Sander M, Lyson T, Thomas GD et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 1996; 9: 121S-138S.
112. Ali Shah I, Whiting PH, Omar G et al. Effects of FK506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. Transplant Proc 1991; 23: 2783-2785.
113. Moochhala SM, Lee EJ, Earnest L et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. Transplant Proc 1991; 23: 2786-2788.
114. Pichard L, Fabre I, Domergue J et al. Effect of FK506 on human hepatic cytochromes P-450: interaction with CyA. Transplant Proc 1991; 23: 2791-2793.
115. Iwasaki K, Matsuda H, Nagase K et al. Effects of 23 drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993; 82: 209-216.
116. Matsuda H, Iwasaki K, Shiraga T et al. Interactions of FK506 (tacrolimus) with clinically important drugs. Res Commun Mol Pathol Pharmacol 1996; 91: 57-64.
117. Christians U, Schmidt G, Bader A et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187-190.
118. Thyss A, Milano G, Renee N et al. Severe interaction between methotrexate and a macrolide-like antibiotic. J Natl Cancer Inst 1993; 85: 582-583 (letter).
119. Wingard JR, Nash RA, Ratanatharathorn V et al. Lack of interation between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. Bone Marrow Transplant 1997; 20: 49-52.
120. Osowski CL, Dix SP, Lin LS et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268-1272.
121. Manez R, Martin M, Raman D et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57: 1521-1523.
122. Assan R, Fredj G, Larger E et al. FK506/fluconazole interaction enhances FK506 nephrotoxicity. Diabet Metab 1994; 20: 49-52.
123. Christians U, Braun F, Sattler M et al. Interactions of FK506 and cyclosporine metabolism. Transplant Proc 1991; 23: 2794-2796.
124. Regazzi MB, Iacona I, Alessiani M et al. Interaction between FK506 and diltiazem in an animal model. Transplant Proc 1996; 28: 1017-1018.
125. Mieles L, Venkataramanan R, Yokoyama I et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 1991; 52: 1086-1087.
126. Furlan V, Perello L, Jacquemin E et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995; 59: 1217-1218.
127. Steeves M, Abdallah HY, Venkataramanan R et al. In vitro interaction of a novel immunosuppressant, FK506, and antacids. J Pharm Pharmacol 1991; 43: 574-577.
128. Campana C, Regazzi MB, Buggia I et al. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 1996; 30: 141-179.
129. Floren LC, Bekersky I, Benet LZ et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-49.